Targeted drug treatment for kidney cancer should be used early

Due to factors such as high blood pressure, obesity, smoking, and high-fat, high-calorie diets, the incidence of kidney cancer has increased significantly in recent years. Kidney cancer, once unknown, has now become a "common disease." Therefore, targeted drug treatment for kidney cancer should be used early. Here is a detailed introduction by a nephrologist:

In the past, surgery was the only effective treatment for kidney cancer. Moreover, even if early-stage kidney cancer patients undergo surgery, 30 to 50 percent of them will develop metastasis and then lose their lives. Therefore, how to help kidney cancer patients find a more targeted and effective treatment method has always been the goal pursued by the medical community. The advent of the targeted therapy drug sunitinib (Sutent) has brought good news to people.

The overall survival of kidney cancer patients who use sunitinib as first-line treatment exceeds two years, which is the first time in the history of kidney cancer treatment. In the past, being able to prolong the life of kidney cancer patients was a luxury, but the advent of this new drug allows patients to not only achieve this goal, but also have a better quality of life. This is undoubtedly good news for kidney cancer patients. Moreover, if kidney cancer patients can start taking the drug in the early stages, they can also prevent tumor metastasis and even save a lot of money on treating complications.

The best way to block kidney cancer is to find the signs of kidney cancer in time and treat it early. Hematuria, back pain and lumps are known as the three typical symptoms of kidney cancer. But if you really treat these problems, it is often too late and the effect will not be good. Therefore, the public must raise their health awareness and have a kidney ultrasound every year after the age of 40. At present, it is not difficult to diagnose kidney cancer early with the comprehensive use of B-ultrasound, CT, MRI and other means.